Amylin replacement therapy in patients with type 1 diabetes

Diabetes Educator

Volumn 32, Issue SUPPL. 3, 2006, Pages

  Edelman, Steven V ^a   Caballero, Leo ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID; GLUCOSE; INSULIN;

ARTICLE; CLINICAL TRIAL; HORMONE SUBSTITUTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; PHYSIOLOGY; WEIGHT GAIN;

AMYLOID; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; GLUCOSE; HORMONE REPLACEMENT THERAPY; HUMANS; INSULIN; WEIGHT GAIN;

EID: 33646734657     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721706288236     Document Type: Article

References (16)

1. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17-20.
2. Jacobs MA, Keulen ET, Kanc K, et al. Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients: a comparison with human regular insulin during a three-meal test period. Diabetes Care. 1997;20:1279-1286.
3. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA. 1998;280:140-146.
4. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
5. Koda JE, Fineman MS, Kolterman OG, Caro JF. 24 hour plasma amylin profiles are elevated in IGT subjects vs. normal controls. Diabetes. 1995;44:238A.
6. Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des. 2001;14:1353-1373.
7. Fineman MS, Giotta MP, Thompson RG, Kolterman OG, Koda JE. Amylin response following Sustacal® ingestion is diminished in type II diabetic patients treated with insulin. Diabetologia. 1996;39:A149.
8. Kruger DF, Gatcomb PM, Owen SK. Clinical implications of amylin and amylin deficiency. Diabetes Educ. 1999;25:389-397.
9. Young AA, Vine W, Gedulin BR, et al. Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Dev Res. 1966;37:231-248.
10. Kolterman O. Paper presented at: American Diabetes Association 63rd Scientific Sessions; June 13-17, 2003; New Orleans, La.
11. Pramlintide [prescribing information]. San Diego, Calif: Amylin Pharmaceuticals, Inc; 2005.
12. Weyer C, Gottlieb A, Kim DD, et al. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care. 2003;26:3074-3079.
13. Presentation to FDA Advisory Committee, July 2001. San Diego, Calif: Amylin Pharmaceuticals, Inc; 2005.
14. Gottlieb A, Velte M, Fineman M, et al. Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 1 diabetes during treatment for 52 weeks [abstract]. Diabetes. 2000;49:A109. Abstract 439-P.
15. Guthrie R. Paper presented at: American Diabetes Association 65th Scientific Sessions; June 10-14, 2005; San Diego, Calif.
16. Levetan C, Want LL, Weyer C, et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care. 2003;26:1-8.